Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
29.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
Next >
BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
November 22, 2021
Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals...
Via
Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
November 16, 2021
Warren Buffet's Berkshire Hathaway added more than 13 million shares.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 16, 2021
Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 16, 2021
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday.
Via
InvestorPlace
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For May 11, 2021
May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is...
Via
Benzinga
36 Stocks Moving in Tuesday's Pre-Market Session
November 16, 2021
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 15, 2021
Gainers Kezar Life Sciences (NASDAQ:KZR) s...
Via
Benzinga
Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript
November 12, 2021
RPRX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
October 29, 2021
Upgrades For Preferred Bank (NASDAQ:
Via
Benzinga
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
September 09, 2021
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of...
Via
Benzinga
Cramer Gives His Opinion On Applied Materials, Coinbase And More
August 26, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter. People who were selling the stock didn...
Via
Benzinga
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
August 17, 2021
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and...
Via
Benzinga
Royal Pharma (RPRX) Q2 2021 Earnings Call Transcript
August 11, 2021
RPRX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Royalty Pharma Q2 Earnings
August 11, 2021
Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year...
Via
Benzinga
Why MorphoSys Stock Sank This Week
June 03, 2021
Investors weren't happy about the drugmaker's wheeling and dealing.
Via
The Motley Fool
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
June 02, 2021
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.
Via
Investor's Business Daily
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For August 11, 2021
August 11, 2021
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is...
Via
Benzinga
Royalty Pharma Insights: Return On Capital Employed
June 02, 2021
Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million. Despite the increase in...
Via
Benzinga
MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma
June 02, 2021
MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of...
Via
Benzinga
Repros Therapeutics (RPRX) Q1 2021 Earnings Call Transcript
May 11, 2021
RPRX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
May 09, 2021
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.
Via
The Motley Fool
Insider Sells Royalty Pharma's Shares
April 14, 2021
A Form 4 filing filed with the SEC on Wednesday, April 14 showed that EVP Reddoch James F. sold 359 shares of Royalty Pharma Inc (NASDAQ:RPRX) at an average price of $42.32...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
April 08, 2021
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an...
Via
Benzinga
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
April 08, 2021
From
Dicerna Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
May 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.